Results 231 to 240 of about 426,371 (334)

Co-targeting MRPS7-23 synergistically enhances cisplatin efficacy to suppress nasopharyngeal carcinoma growth and metastasis. [PDF]

Int J Biol Sci
Cao Z, Pan C, Liu Z, Quan Q, Li M, Huang Y, Liang C, Chen Y, Fan T, Chen P, Kai F, Zhu S, Li S, Su X, Wang F, Fu L, Zhang B.   +16 more
europepmc   +1 more source

ATP6V0D2 drives triple-negative breast cancer progression and inhibits cisplatin sensitivity by promoting PHLPP2 lysosomal degradation

Jingyu Zhang, Congbo Cao, Yang Hong-yu, Liu Yang, Meiqi Wang, Xiaohan Liu, Xin Hao, Yuanyuan Zhang, Xiaohan Wang, Zhenchuan Song   +9 more
openalex   +1 more source

3D Hydrogel Cell Cultures and Their Biomedical Applications

Advanced NanoBiomed Research, EarlyView.
The review highlights the advantages of hydrogel‐based 3D cell cultures over traditional 2D models. These hydrogels closely mimic natural cellular environments, improving research in tissue engineering, drug discovery, cancer studies, and neuroscience.
Tri Lan Thai, Arushi Manchanda, Sarah L. Higginbottom, Estrella Sanz Rodriguez, Richard Wilson, Eva Tomaskovic‐Crook, Jeremy M. Crook, Brett Paull   +7 more
wiley   +1 more source

FDA-Approved MEK1/2 Inhibitor, Trametinib, Protects Mice from Cisplatin and Noise-Induced Hearing Loss [PDF]

Richard D. Lutze, Matthew A. Ingersoll, Regina G. Kelmann, Tal Teitz   +3 more
openalex   +1 more source

Engineering Ultrasound Contrast Agents for Targeted Therapeutics: A Theranostic Approach to Drug Delivery, Gene Therapy, and Immunomodulation

Advanced NanoBiomed Research, EarlyView.
Ultrasound contrast agents, including microbubbles and nanobubbles, transform imaging and targeted therapy through precise engineering of size, shell composition, and surface properties. This review explores how these innovations enable tissue‐specific delivery, enhance therapeutic efficacy, and extend applications from vascular imaging to tumor ...
Ashkan Seza, Kimia Mozahheb Yousefi, Sara Minaeian   +2 more
wiley   +1 more source

Uromodulin alleviates fibrosis in acute kidney injury to chronic kidney disease transition by reducing EGFR. [PDF]

Cell Commun Signal
Xing Z, Gong K, Wang N, Bai L, Hu N, Song D, Chen Y.   +6 more
europepmc   +1 more source

Plasma Proteomics Identifies TAOK3 as a Potential Biomarker of Rheumatoid Arthritis Activity and a Novel Therapeutic Target

Arthritis &Rheumatology, Accepted Article.
Objective Bone destruction associated with active rheumatoid arthritis (RA) remains a major therapeutic challenge, with a lack of reliable molecular markers reflecting bone injury. This study aims to identify novel biomarkers linked to bone destruction in active RA through proteomic analysis, providing new strategies for precise monitoring and targeted
Pengfei Xin, Wenzhen Li, Xinyu A, Jun Shen, Xiaohui Meng, Yanqin Bian, Haihui Han, Zheng Xiang, Lei Ran, Songtao Sun, Jun Xie, Tao Yue, Qi Zhu, Xiaoming Zhang, Lu Xie, Lianbo Xiao   +15 more
wiley   +1 more source

Preliminary Evaluation of an Injectable Therapeutic for Cisplatin Ototoxicity Using Neuronal SH-SY5Y Cells. [PDF]

Medicines (Basel)
Hong M, Kedeshian K, Hoffman L, Kita A.
europepmc   +1 more source

Long–Term Renal Outcomes after Cisplatin Treatment

, 2016
Sheron Latcha, Edgar A. Jaimes, Sujata Patil, Ilya Glezerman, Swati Mehta, Carlos D. Flombaum   +5 more
openalex   +1 more source

Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study

British Journal of Clinical Pharmacology, EarlyView.
Aims In the AEGEAN study, perioperative durvalumab plus platinum‐based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non‐small‐cell lung cancer (NSCLC) demonstrated a favourable benefit–risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure–response (ER) relationships of durvalumab in patients ...
Xiaoying Zhao, Junjie Ding, Jiajia Zhao, Ling Zhang, Aburough Abegesah, Yu‐qian Zhang, Cathy O'Brien, Gary J. Doherty, Allen C. Chen, KyoungSoo Lim, Song Ren, Peiming Ma, Diansong Zhou   +12 more
wiley   +1 more source